WO1991013974A1 - Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b - Google Patents

Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b Download PDF

Info

Publication number
WO1991013974A1
WO1991013974A1 PCT/US1991/001649 US9101649W WO9113974A1 WO 1991013974 A1 WO1991013974 A1 WO 1991013974A1 US 9101649 W US9101649 W US 9101649W WO 9113974 A1 WO9113974 A1 WO 9113974A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
mab
cells
cell
antibodies
Prior art date
Application number
PCT/US1991/001649
Other languages
English (en)
Inventor
John M. Pesando
Original Assignee
The Biomembrane Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Biomembrane Institute filed Critical The Biomembrane Institute
Publication of WO1991013974A1 publication Critical patent/WO1991013974A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Definitions

  • Monoclonal antibody and immunoconjugates for the treatment and detection of B cell disorders.
  • the present invention relates generally to compositions for use within methods for the treatment and detection of B cell disorders and, more specifically, to the use of immunoconjugates, formed from at least one agent and an anti-CD 19 antibody, in combination with an antibody specific for the surface immunoglobulin of a target B cell.
  • cancer Despite enormous investments of financial and human resources, cancer remains one of the major causes of death.
  • One type of cancer is malignancies of B cells, e.g., Hodgkin's lymphoma, Burkitt's lymphoma and chronic lymphocytic leukemia. These malignancies represent 5% of all cancer deaths in the United States. Conventional forms of therapy, such as radiation and chemotherapy, have had limited success.
  • B cells e.g., other B cell disorders have posed problems in treatment.
  • Autoimmune diseases are examples of such non- cancer B cell disorders. Examples of autoimmune diseases include rheumatoid arthritis, Graves' disease and myasthenia gravis.
  • the present invention provides an immunoconjugate for use within a method for treating a B cell disorder in a warm ⁇ blooded animal.
  • the immunoconjugates comprise at least one therapeutic agent coupled to an antibody that selectively binds to the CD19 antigen, in combination with an antibody that selectively binds to the surface immunoglobulin of a target B cell.
  • the present invention provides an immunoconjugate for use within a method for detecting a B cell associated with a B cell disorder.
  • the immm oconjugates comprise at least one diagnostic agent coupled to an antibody that selectively binds to the CD19 antigen, in combination with an antibody that selectively binds to the surface immunoglobulin of a target B cell.
  • a representative monoclonal antibody (MAb), J3-119 that selectively binds to the CD19 antigen is provided.
  • a cell line, designated by ATCC No. HB 10383, that produces J3-119 is also provided.
  • the present invention provides an immunoconjugate comprising at least one agent coupled to the monoclonal antibody J3-119 or a monoclonal antibody that competitively inhibits the formation of an immunocomplex between J3-119 and the CD19 antigen.
  • Preferred agents include therapeutic and diagnostic agents.
  • Figure 1 graphically illustrates that anti-CD 19 MAb is internalized and degraded during anti-Ig-induced comodulation of CD 19. Identical cultures of
  • SKLY18 B lymphoma cells are incubated in parallel with 12 ⁇ I-labeled anti-CD19
  • Figure 2 graphically illustrates that anti-Ig MAb is rapidly internalized and degraded when cells are incubated with anti-Ig MAb at 37°C.
  • SKLY18 B lymphoma cells are incubated with 12 -*I-labeled anti-Ig MAb alone at 37°C as described in Figure 1. Aliquots are removed at the times indicated and assayed for internalized, cell-bound, and free MAb (intact and antibody fragments).
  • Figure 3 pictorially depicts cocapping studies which confirm that anti-CD 19 MAb is internalized and degraded when cells are incubated with anti- Ig MAb.
  • Cells are pretreated with fluoresceinated anti-CD 19 MAb at 4°C, washed, and coincubated with either isotype-matched anti-CD4 MAb (Panels A-
  • Figure 4 graphically illustrates that coincubation of cells with both anti-Ig and anti-CD19 MAb selectively increases the rate and extent of CD19 modulation.
  • CD 19 expression is monitored on SKLY18 cells incubated with the following MAb (each at 10 ⁇ g /ml) at 37°C: anti-CD4 (J5-19), anti-Ig (HB43), anti-CD19 (J3-119), and anti-Ig plus anti-CD19.
  • the percent of detectable CD19 remaining on the cell surface at 2.25 and 5 hours is indicated.
  • the present invention is directed toward methods and compositions for the treatment and detection of B cell disorders.
  • the disclosure of the present invention shows that the combination of an antibody to surface immunoglobulins on B cells and an antibody to the CD19 antigen on B cells can be used for the rapid and specific delivery of agents, via CD19-specific immunoconjugates, to the intracellular compartment of targeted B cells.
  • B lymphocytes are responsible for the ultimate production of antibody molecules.
  • B cells express both surface immunoglobulin (slg) and non-immunoglobulin cell surface markers, slgs recognize and bind antigens.
  • the structure of slg is composed of two heavy polypeptide chains and two light polypeptide chains.
  • the heavy chains may be a gamma or mu type and the light chains a kappa or lambda type. In a given slg molecule, all the heavy chains are identical and similarly all the light chains are identical.
  • light and heavy chains have both constant and variable regions, i.e., regions where the amino acid sequence is relatively the same from molecule to molecule, or relatively different, respectively.
  • variable regions of an immunoglobulin contain the structures responsible for the antigenic specificity of the immunoglobulins.
  • the antigen binding site of every immunoglobulin molecule is structurally unique and, therefore, each immunoglobulin has unique antigenic determinants not shared by other immunoglobulin molecules. These unique determinants are one type of antigenic determinant ("idiotope") that distinguish a particular immunoglobulin.
  • idiotope one type of antigenic determinant
  • Other idiotopes may also be in the variable regions but outside the antigen-binding site. The collection of idiotopes (i.e., idiotype) distinguish immunoglobulins, and thus, B cells.
  • CD19 antigen is a non-immunoglobulin 85-95 kilodalton cell surface protein residing on B cells. As disclosed within the present invention, CD19 is a phosphorylated glycoprotein. CD19 is B cell-specific and has the broadest B cell reactivity of all known B cell surface proteins. It is common to all B cells except plasma cells (i.e., a pan-B surface antigen). A number of antibodies specific for CD19 (“anti-CD19 antibodies”) have been reported.
  • the combination of an antibody which binds to slg on B cells and an antibody to CD 19 in the form of a CD19-specific immunoconjugate
  • an antibody to CD 19 in the form of a CD19-specific immunoconjugate
  • An advantage of this dual antibody approach is that the cytoplasm of a target cell is exposed to higher levels of CD19-specific immunoconjugates, and therefore of the transported diagnostic or therapeutic agent, than when the CD19-specific immunoconjugates are used alone.
  • CD19-specific immunoconjugates by target cells treated with both antibodies. This accelerated uptake may minimize toxicity of these immunoconjugates to scavenger cells of the reticuloendothelial system.
  • the more rapid, specific, and efficient delivery of CD19-specific immunoconjugates to target cells by the dual antibody approach of the present invention increases the specificity and efficacy of these immunoconjugates while reducing their toxicity.
  • a B cell disorder may be treated by administering to a warm-blooded animal, such as a human, an effective amount of an antibody that selectively binds to the surface immunoglobulin of a target B cell, in combination with an immunoconjugate comprising at least one therapeutic agent coupled to an antibody that selectively binds to the CD 19 antigen.
  • a warm-blooded animal such as a human
  • an immunoconjugate comprising at least one therapeutic agent coupled to an antibody that selectively binds to the CD 19 antigen.
  • This method is applicable to a wide variety of B cell disorders, including malignancies and autoimmune diseases.
  • Representative B cell malignancies include non-Hodgkin's lymphoma, Burkitt's lymphoma, and chronic lymphocytic leukemia.
  • Representative autoimmune diseases i.e., diseases in which an individual is producing antibodies against one or more of its own proteins, include juvenile and adult rheumatoid arthritis, Graves' disease, and myasthenia
  • the antibody may be an anti-Ig heavy chain antibody, i.e., anti-gamma or anti-mu, or an anti-Ig light chain antibody, i.e., anti-kappa or anti-lambda.
  • the anti-Ig light or heavy chain antibodies may be polyclonal or monoclonal antibodies. Briefly, polyclonal antibodies may be produced by immunization of an animal and subsequent collection of its sera. It is generally preferred to follow the initial immunization with one or more boosters prior to sera collection.
  • MAbs monoclonal antibodies
  • Suitable MAbs include those of murine or human origin, or chimeric antibodies such as those which combine portions of both human and murine antibodies (i.e., antigen binding region of murine antibody plus constant regions of human antibody).
  • Human and chimeric antibodies may be produced using methods known by those skilled in the art. Human antibodies and chimeric human-mouse antibodies are advantageous because they are less likely than murine antibodies to cause the production of anti-antibodies when administered clinically.
  • MAbs may be generally produced by the method of Kohler and Milstein (Nature 2 ⁇ :495-497, 1975; Eur. J. Immunol. 6..511-519, 1976). Briefly, the lymph nodes and/or spleens of an animal immunized with an Ig chain are fused with myeloma cells to form hybrid cell lines ("hybridomas" or "clones"). Each hybridoma secretes a single type of immunoglobulin specific for the Ig chain, and, like the myeloma cells, has the potential for indefinite cell division.
  • MAbs which selectively bind to a particular Ig chain are commercially available, e.g., MAb HB43 (1410KG7) specific for Ig gamma chain may be obtained from the American Type Culture Collection.
  • the particular anti-heavy chain antibody (i.e., anti-gamma versus anti-mu) or the particularly anti-light chain antibody (i.e., anti-kappa versus anti- lambda) selected depends upon the Ig phenotype, i.e., heavy and light chain specificity, of the target B cell. For example, since the cells of a B cell tumor are monoclonal in nature, all the cells of the target tumor will have the same Ig phenotype.
  • the Ig phenotype may be determined using one of a variety of methods known by those skilled in the art. For example, washed cells are incubated separately with a series of antibodies specific for immunoglobulin gamma, mu, kappa, or lambda chains or with nonreactive isotype-matched control antibodies or with antibodies specific for other B cell- associated antigens, for 30 minutes at 4°C. Cells are washed, and bound antibodies are detected, e.g., using a standard indirect immunofluorescence binding assay.
  • the immunoglobulin phenotype of the tumor cells is indicated by the specificity of the anti-immunoglobulin antibodies which they bind.
  • tumor cells are identified both by size and by their expression of tumor-associated antigens. Since tumor cells are monoclonal, they are further distinguished from normal B cells by their expression of a single immimoglobulin surface phenotype.
  • the antibody that selectively binds to slg of a target B cell may be an anti-idiotype antibody.
  • the intact cells or slg isolated from the cells can be used to produce anti-idiotype antibodies.
  • Balb/c mice are immunized with either the purified idiotype antibody secreted by a patient's tumor or with a patient's tumor cells, depending on availability.
  • Resulting hybridomas which secrete anti-idiotype antibodies are identified first by screening supematants from hybridoma cultures for positive reactivity with the immunogen (idiotype antibody or tumor cell) using any one of a series of binding assays (e.g., immunofluorescence, radioimmune, or EHJSA). Antibodies from reactive clones are further screened for negative reactivity with other purified human immunoglobulins, e.g., by radioimmunoassay. Antibodies which react with other purified human immunoglobulins are discarded.
  • a series of binding assays e.g., immunofluorescence, radioimmune, or EHJSA.
  • hybridomas which produce supematants with antibodies which only react with the immunogen are further tested for binding to patient tumor cells which have been incubated with anti-immunoglobulin antibodies (i.e., anti-gamma, anti-mu, anti-lambda, anti- kappa) which remove or modulate the surface immunoglobulin on these cells.
  • Anti-idiotype antibodies show decreased binding to cells whose surface immunoglobulin has been modulated.
  • the antigen identified by the putative anti- idiotype antibody is determined (e.g., by immune precipitation) and compared with that identified by anti-immunoglobulin antibody on the same cells.
  • Tumor cells from the patient are surface radiolabeled, e.g., with iodine ( I), and solubilized in nonionic detergent.
  • Surface immunoglobulin is precipitated by anti- idiotype and anti-immunoglobulin antibodies and analyzed by sodium dodecyl- sulfate polyacrylamide gel electrophoresis.
  • the target antigen of anti- idiotype antibodies is tested for cocapping by anti-immunoglobulin antibodies using standard procedures.
  • the other antibody in the dual antibody methods of the present invention is an antibody, in the form of an immunoconjugate, that selectively binds, i.e., with an affinity of about 10 7 liters/mol or higher, to CD19.
  • Suitable anti-CD19 antibodies include antibodies provided by the present invention as well as those described by others.
  • the anti-CD 19 antibodies may be polyclonal or monoclonal. The discussion above regarding polyclonal and monoclonal antibodies applies equally here.
  • the present invention provides a representative example of a suitable monoclonal antibody, J3-119, and a cell line, designated by ATCC No. HB 10383, that produces it.
  • MAb J3-119 selectively binds to CD19 from a variety of organisms.
  • the J3-119 anti-CD19 MAb is unique among CD19-specific antibodies in its ability to bind to the B cells of nonhuman primates M. Mulatto, M. Nemestrina, P. Cynocephalus), just as it does in human.
  • An antibody that selectively binds to CD 19 is coupled to one or more therapeutic agents to form a CD19-specific immunoconjugate.
  • Suitable agents include radionuclides, differentiation inducers, drugs, toxins, and derivatives thereof.
  • Preferred radionuclides include ⁇ Y, 12 , 12 ⁇ I, ⁇ I, 18°R e , l°°Re, 211 At, and 212 Bi.
  • Preferred dmgs include methotrexate, and pyrimidine and purine analogs.
  • Preferred differentiation inducers include phorbol esters and butyric acid.
  • Preferred toxins include ricin, abrin, diptheria toxin, cholera toxin, gelonin, Pseudomonas exotoxin, Shigella toxin, and pokeweed antiviral protein.
  • An agent may be coupled to, e.g., covalently bonded to, an anti- CD19 antibody either directly or indirectly, e.g., via a linker group.
  • a direct reaction between an agent and an antibody is possible when each possesses a substituent capable of reacting with the other.
  • a nucleophilic group such as an amino or sulfhydryl group
  • on one may be capable of reacting with a carbonyl-containing group, such as an anhydride or an acid halide, or with an alkyl group containing a good leaving group, e.g., a halide, on the other.
  • a linker group can function as a spacer to distance an antibody from an agent in order to avoid interference with binding capabilities.
  • a linker group can also serve to increase the chemical reactivity of a substituent on an agent or an antibody, and thus increase the coupling efficiency. An increase in chemical reactivity may also facilitate the use of agents, or functional groups on agents, which otherwise would not be possible.
  • a carboxyl group for example, may be activated. Activation of a carboxyl group includes formation of an "active ester," such as a sucdnimidyl ester.
  • active ester is known to refer to esters which are highly reactive in nucleophilic substitution reactions.
  • linker group which is cleavable during or upon internalization into a cell.
  • a number of different cleavable linker groups have been described previously.
  • the mechanisms for the intracellular release of an agent from these linker groups include cleavage by reduction of a disulfide bond (e.g., U.S. Patent No.4,489,710, to Spitler), by irradiation of a photolabile bond (e.g., U.S. Patent No. 4,625,014, to Senter et al.), by hydrolysis of derivatized amino acid side chains (e.g., U.S. Patent No.
  • immunoconjugates with more than one agent may be prepared in a variety of ways.
  • more than one agent may be coupled directly to an antibody molecule, or linkers which provide multiple sites for attachment can be used.
  • a carrier can be used.
  • a carrier may bear the agents in a variety of ways, including covalent bonding either directly or via a linker group. Suitable carriers include proteins such as albumins (e.g., U.S. Patent No.
  • a carrier may also bear an agent by noncovalent bonding or by encapsulation, such as within a liposome vesicle (e.g., U.S. Patent Nos. 4,429,008 and 4,873,088).
  • Carriers specific for radionuclide agents include radiohalogenated small molecules and chelating compounds. For example, U.S. Patent No. 4,735,792, to Srivastava, and European Patent Application Publ. No.
  • a radionuclide chelate may be formed from chelating compounds that include those containing nitrogen and sulfur atoms as the donor atoms for binding the metal, or metal oxide, radionuclide.
  • U.S. Patent No. 4,673,562 to Davison et al., and European Patent Application Publ. No. 0188256 disclose representative chelating compounds and their synthesis.
  • An immunoconjugate such as those described above is administered in combination with an antibody that selectively binds to the slg of a target B cell.
  • routes of administration may be used. Typically, administration will be intravenous or intracavitary, e.g., in pleural or peritoneal cavities, or in the bed of a resected tumor. While simultaneous administration of an anti-slg antibody and a CD19-specific immunoconjugate may be preferred for convenience, their administration may be sequential.
  • the precise optimum dose for a particular anti- slg antibody may vary, depending in part on the antibodies used, the antigen density on the tumor, the amount of cross-reactive circulating immunoglobulin, and the bulk of tumor present.
  • the affinity and rate of clearance of individual antibodies from the body may also vary. Since anti-idiotype antibodies are more specific than anti-heavy or anti-light chain antibodies, the dosage may be less. Generally, however, an effective amount of an anti-slg antibody will be from about 0.01 to about 100 mg per kg body weight. Similarly, the precise optimum dose for a particular CD19-specific immunoconjugate may vary. As above, the optimum immunoconjugate dose will vary with the antigen density on the tumor and the bulk of tumor present. Moreover, agents vary with respect to their potency and antibodies vary with respect to binding affinity. Generally, however, an effective amount of an immunoconjugate of the present invention will be from about 0.01 to about 10 mg per kg body weight.
  • Suitable carriers or diluents include physiological saline.
  • a B cell disorder may be detected by administering to a warm-blooded animal, such as a human, an effective amount of an antibody that selectively binds to the surface immunoglobulin of a target B cell, in combination with an immunoconjugate comprising at least one diagnostic agent coupled to an antibody that selectively binds to the CD 19 antigen.
  • a warm-blooded animal such as a human
  • an immunoconjugate comprising at least one diagnostic agent coupled to an antibody that selectively binds to the CD 19 antigen.
  • this method will be used to determine the location(s) of a B cell disorder or to monitor a patient for residual or recurrent targeted B cells.
  • Suitable diagnostic agents include those which are detectable directly or indirectly.
  • suitable diagnostic agents include a reporter group such as a radionuclide or magnetic imaging enhancer.
  • Preferred radionuclides include 99m- Cj and 125 reparation of a magnetic imaging enhancer coupled to an anti-CD19 antibody may be effected by a variety of methods (e.g., U.S. Patent No. 4,735,210, to Goldenberg). It will be evident to those skilled in the art that the method of detecting a diagnostic agent will be dependent upon the type of agent utilized. A variety of equipment, such as ionizing radiation detectors, is commercially available for the detection of diagnostic agents.
  • MAb HB43 (1410KG7) specific for immunoglobulin gamma chain was obtained from the American Type Culture Collection (ATCC, Rockville, Md.).
  • MAb J3-119 was prepared as follows. BALB/c mice were immunized with cells from the malignant human B cell line BALM-4, which was established from a patient with diffuse poorly differentiated lymphocytic lymphoma. These cells express slgG-kappa, CD19, and CD20, confirming that they are of B cell origin. They are negative for the T cell-associated CD3, CD4, and CD8 antigens.
  • MAb J3-119 was produced by fusing spleen cells of immunized BALB/c mice with the murine plasmacytoma cell line P3/NSl/l-Ag4-l. An indirect immunofluorescence assay (described in section E below) was used to detect clones producing MAb which react with the immunizing cell population. Such clones were then tested against a panel of hematopoietic cell populations. MAb J3-119 reacts exclusively with B cells. The hybridoma was then subcloned by limiting dilution without feeder cells and retested.
  • MAb from original and subcloned hybridomas were compared for their ability to bind to the immunizing cell population under conditions of antibody excess to assess the possible presence of multiple antibody-producing clones in the original hybridoma.
  • Such antibodies were considered to be identical if they produced identical immunofluorescence profiles when assayed in parallel and failed to produce additive binding patterns with the use of an indirect immunofluorescence assay.
  • Serotyping indicates that J3-119 is of the IgG ⁇ subclass.
  • Antibodies were obtained from the ascites of tumor-bearing mice.
  • MAb were purified from murine ascites using a protein A-Sepharose column (Sigma Chemical Co., St. Louis, Mo.).
  • IgGj, MAb were loaded under high salt, high pH conditions (0.1 M glycine, 3 M NaCl, pH 8.9), and eluted with 0.1 M pH 6.0 citrate buffer. After elution, MAb were exhaustively dialyzed against pH 7.4 PBS. Antibody purity was confirmed by demonstration of single heavy and light chain Ig bands on SDS-PAGE.
  • Antibody Radiolabeling Affinity purified MAb (250 ⁇ gm) was trace-labeled with 125 I (500 ⁇ Ci) using Iodo-Beads (Pierce Chemical Co., Rockford, IL) with removal of free 125 I by gel filtration. Protein concentration was determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, Calif.). Specific activities obtained ranged from 0.95 to 1.04 ⁇ Ci/ ⁇ gm. Immunoreactivity was determined by incubating 125 I-labeled antibody (10 mg/ml) with increasing numbers of cells to 2.5 x 10 7 /ml.
  • FITC-labeled MAb were screened on antigen positive and negative cell lines by flow cytometry to determine optimum working dilutions.
  • Antibody binding to target cells was determined by using either directly fluoresceinated MAb or by employing fluoresceinated goat anti-mouse antibody (Tago, Burlingame, Calif.) in a standard indirect immunofluorescence binding assay. Antibody binding in both assays was monitored on the Epics
  • ⁇ 2 P ⁇ 4 Cells to be metabolically labeled with ⁇ 2 P ⁇ 4 were washed and incubated in phosphate-free MEM medium (GIBCO) for 2 hours at 37°C. They were then resuspended in phosphate-free medium at 1 x 10 '/ml and incubated with 1-2 mCi of 32 P ⁇ 4 (Amersham, Arlington Heights, DI.) for 1 hour at 37°C. After washing, cells were lysed as described above, except that 50 mM NaF, 5 mM sodium pyrophosphate, and 2 mM sodium orthovanadate were added to inhibit phosphatase enzymes. Lysates were passed through a Sephadex G-25 column (Pharmacia, Piscataway, N.J.) to remove free phosphate.
  • Radiolabeled detergent solubilized cell lysates were applied to a Sephadex G-25 column to isolate radiolabeled proteins. Lysates were then precleared by incubating them with affinity purified rabbit anti-mouse Ig that had been covalently coupled to Sepharose CL4B (R/M-Sepharose). Individual MAb were incubated overnight in parallel at 4°C with R/M-Sepharose. Antibody- matrix complexes were then washed and incubated for 16 hours at 4°C with aliquots of the appropriate precleared radiolabeled lysate.
  • SKLY18 cells metabolically labeled with 32 P ⁇ 4 were again incubated in parallel with either an isotype-matched control MAb or anti-gamma (50 ⁇ gm/ml) under modulating conditions. Equal numbers of cells were harvested and 32 P ⁇ 4-labeled CD 19 antigens isolated and compared by immune precipitation at 0, 30, or 90 minutes. Autoradiographs of SDS gels of the immune precipitations show that CD 19 is intensely labeled with 32 P and, therefore, indicate that this transmembrane protein is phosphorylated. Weak but consistent and specific 32 P-labelling of CD45 is also noted under these conditions, indicating that it too is a phosphoprotein. Comparative studies indicate that there is approximately 70% as much 32 P-labeled CD 19 isolated from anti-Ig-treated cells versus anti-CD4-treated cells at both 60 and 90 minutes.
  • the SKLY18 B lymphoma cell line was cultured in RPMI 1640 medium (GIBCO, Grand Island, N.Y.) supplemented with 10% fetal bovine serum (Hyclone), glutamine (GIBCO), nonessential amino acids (GIBCO), and penicillin/streptomycin (GIBCO) at 37°C in a 5% CO2 atmosphere with 100% humidity. Viability of all cells used in these experiments was greater than 95%.
  • Modulation of surface antigens was performed by incubating cells (1 x 10"/ml) under standard tissue culture conditions with 10 ⁇ g/ml of purified MAb for the times indicated. Identical cultures were incubated with isotype-matched MAb to slg, CD 19, or CD4 antigens at 37°C, washed, incubated with MAb specific for test antigens at 4°C, and analyzed. Changes in the binding of directly fluoresceinated MAb are expressed by dividing the mean channel of fluorescence observed on reactive-antibody treated cells by that observed with control (anti- CD4) treated cells after correcting for nonspecific binding.
  • CD19 expression is monitored on SKLY18 cells incubated with the following MAb (each at 10 ⁇ gm/ml) at 37°C: anti-CD4 (J5-19), anti-Ig (HB43), anti-CD19 (J3- 119), and anti-Ig plus anti-CD19. The percent of detectable CD19 remaining on the cell surface at 225 and 5 hours is indicated. Incubating cells with MAb to either slg or CD19 reduces expression of CD19; incubating cells with MAb to both antigens simultaneously increases both the rate and extent of CD19 modulation.
  • CD19 expression is followed using an indirect immunofluorescence assay and confirmed using directly fluoresceinated anti-CD 19 MAb when anti-CD4 and anti- IgG MAb are the modulating agents. Modulation of slgG on SKLY18 by anti-IgG MAb is greater than 95% complete by 2 hours, permitting accurate assessment of CD19 expression using directly fluoresceinated reagents.
  • Cells are pretreated with fluoresceinated anti-CD19 MAb at 4°C, washed, and coincubated with either isotype-matched anti-CD4 MAb (Panels A-D) or anti-lambda MAb (Panels E-H) at 37°C. Cells were removed, washed, and analyzed at 0, 20, 40, 60, 90, and 120 minutes. Results at 40, 60, 90, and 120 minutes are indicated in panels A and E, B and F, C and G, and D and H, respectively.
  • SKLY18 cells and incubated for 40 minutes at 4°C. Cells were then washed three times in cold media and resuspended at 1 x 10' cells/ml. 1 x 10" cells (100 ⁇ l) were added to a series of tubes containing 400 ⁇ l of RPMI 1640 media with 0.1% bovine serum albumin and either anti-lambda or anti-CD4 MAb (both at 15 ⁇ gm/ml) and incubated at 37°C for varying times. At each time point, 3 tubes (3 x 10 6 cells) from both the anti-lambda and control lots were removed, centrifuged at 4°C, and washed once, saving both supematants for counting.
  • TCA trichloroacetic acid
  • radiolabeled anti-CD19 MAb is rapidly removed from the cell surface, internalized, and then degraded, with release of antibody fragments into the tissue culture media, in the presence of anti-Ig but not anti-CD4 MAb.
  • Identical cell cultures are incubated in parallel with - ⁇ I-labeled anti-CD19 MAb (J3-119). Cells are also incubated with 15 ⁇ gm/ml of either anti- CD4 control MAb ( Figure 1A) or anti-Ig MAb ( Figure IB). All other conditions are the same. Aliquots from the two cultures are removed at the times indicated and assayed for radiolabeled internalized, cell-bound, and free MAb (intact and antibody fragments).
  • Tables I and II quantify the data in Figures 1 and 2.
  • the percent of degraded, radiolabeled MAb (Table I) reflects the amount of MAb that has passed through the cell during the course of the experiment.
  • the amount of cell-associated and acid wash-resistant radioactivity in Figures 1 and 2 is expressed as a percent of the total amount of recovered radioactivity at each time point (minutes).
  • Bold characters indicate 125 I-labeled MAb.
  • the amount of TCA nonprecipitable radioactivity in the culture supernatant in Figures 1 and 2 is expressed as a percent of the total amount of recovered radioactivity at that time point (minutes).
  • Bold characters indicate 1 I-labeled MAb.
  • CD19 is comodulated by anti-Ig MAb
  • CD19 is unaffected by specific MAb-mediated modulation of Tfr/CD71 or CALLA/CDIO. Therefore, comodulation of CD19 is specifically associated with modulation of slg by anti-Ig MAb and not with the modulation process itself.
  • SKLY 18 cells quantitative expression of slg and Tfr is compatible while that of CALLA/CDIO is lower.
  • SKLY18 B lymphoma cells were incubated for 20 hours with purified modulating MAb, washed, and incubated with purified directly fluoresceinated MAb specific for test antigen. Fluorescence was monitored using an Epics Profile cytofluorograph with fluorescence displayed in logarithmic mode. Extent of self- modulation is measured using an indirect immunofluoresce binding assay. Percent change in antigen expression relative to control is shown for a representative experiment. Experiments were performed using isotype-matched modulating MAb. Numbers in parenthesis after each test antigen indicate its mean channel of staining in the control sample as measured using directly fluoresceinated MAb.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédés et compositions de traitement de troubles des lymphocytes B. On peut traiter des troubles des lymphocytes B par l'emploi d'un anticorps se liant sélectivement à l'immunoglobuline de surface (Igs) d'un lymphocyte B cible, en combinaison avec un immunoconjugué comprenant au moins un agent thérapeutique couplé à un anticorps se liant sélectivement à l'antigène CD19 sur les lymphocytes B. L'invention concerne également des procédés et des compositions de détection de troubles des lymphocytes B.
PCT/US1991/001649 1990-03-14 1991-03-12 Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b WO1991013974A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49357790A 1990-03-14 1990-03-14
US493,577 1990-03-14
US56015490A 1990-07-31 1990-07-31
US560,154 1990-07-31

Publications (1)

Publication Number Publication Date
WO1991013974A1 true WO1991013974A1 (fr) 1991-09-19

Family

ID=27051123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/001649 WO1991013974A1 (fr) 1990-03-14 1991-03-12 Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b

Country Status (2)

Country Link
AU (1) AU7566991A (fr)
WO (1) WO1991013974A1 (fr)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017625A1 (fr) * 1994-12-06 1996-06-13 Cambridge University Technical Services Limited Modulation de la reponse immune
WO2000074718A1 (fr) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
EP1393750A2 (fr) 1992-04-07 2004-03-03 Immunomedics, Inc. Conjugués pour le traitement d'une maladie immunitaire
EP1543839A1 (fr) * 1999-06-09 2005-06-22 Immunomedics, Inc. Immunotherapie de troubles auto-immuns à l'aide d'anticorps ciblant les cellules B
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US7993925B2 (en) 2005-05-31 2011-08-09 Cold Spring Harbor Laboratory Methods for producing microRNAs
EP2359139A2 (fr) * 2008-11-07 2011-08-24 National Jewish Health Diagnostic et traitement des maladies auto-immunes par ciblage des cellules b auto-immunes (« cbai »)
EP2383297A1 (fr) 2006-08-14 2011-11-02 Xencor Inc. Anticorps optimisés ciblant le CD19
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US8734792B2 (en) 2002-02-21 2014-05-27 Duke University Reagents and treatment methods for autoimmune diseases
US8871216B2 (en) 2005-04-06 2014-10-28 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US9028833B2 (en) 2012-12-13 2015-05-12 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9993550B2 (en) 1999-05-07 2018-06-12 Genentech, Inc. Treatment of pemphigus
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10266605B2 (en) 2016-04-27 2019-04-23 Immunomedics, Inc. Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US10322176B2 (en) 2002-03-01 2019-06-18 Immunomedics, Inc. Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10954305B2 (en) 2016-02-10 2021-03-23 Immunomedics, Inc. Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
US11180559B2 (en) 2005-03-03 2021-11-23 Immunomedics, Inc. Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
EP0317156A1 (fr) * 1987-11-09 1989-05-24 Becton, Dickinson and Company Méthode pour analyser des cellules hématopoietiques d'une échontillon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
EP0317156A1 (fr) * 1987-11-09 1989-05-24 Becton, Dickinson and Company Méthode pour analyser des cellules hématopoietiques d'une échontillon

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF EXPERIMENTAL MEDICINE, Vol. 170, No. 6, 1 December 1989, J.M. PESANDO, "CD19 is Functionally and Physically Associated With Surface Immunoglobulin", pages 2159-2164. *
TISSUE ANTIGENS, Vol. 33, No. 2, 1989, J.M. PESANDO, "Comparison of the Epitope Specificity of 14 Anti-CD19 Monoclonal Antibodies", page 136. *

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1393750B1 (fr) * 1992-04-07 2009-09-02 Immunomedics, Inc. Anticorps pour le traitement d'une maladie immunitaire
EP1393750A2 (fr) 1992-04-07 2004-03-03 Immunomedics, Inc. Conjugués pour le traitement d'une maladie immunitaire
WO1996017625A1 (fr) * 1994-12-06 1996-06-13 Cambridge University Technical Services Limited Modulation de la reponse immune
US6238670B1 (en) 1994-12-06 2001-05-29 Cambridge University Technical Services Limited Compositions and methods employing a ligand for CD21 or CD19 for modulating the immune response to an antigen
US6891027B2 (en) 1994-12-06 2005-05-10 Cambridge University Technical Services Limited Modulating the immune response
US9993550B2 (en) 1999-05-07 2018-06-12 Genentech, Inc. Treatment of pemphigus
US8481003B2 (en) 1999-05-10 2013-07-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8367037B2 (en) 1999-05-10 2013-02-05 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8343496B2 (en) 1999-05-10 2013-01-01 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8119101B2 (en) 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US8846002B2 (en) 1999-05-10 2014-09-30 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8986699B2 (en) 1999-05-10 2015-03-24 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
WO2000074718A1 (fr) * 1999-06-09 2000-12-14 Immunomedics, Inc. Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b
EP2289551A1 (fr) * 1999-06-09 2011-03-02 Immunomedics, Inc. Immunothérapie de troubles auto-immunitaires utilisant des anticorps qui ciblent les lymphocytes B
US7641901B2 (en) 1999-06-09 2010-01-05 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
AU782160B2 (en) * 1999-06-09 2005-07-07 Immunomedics Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
EP1543839A1 (fr) * 1999-06-09 2005-06-22 Immunomedics, Inc. Immunotherapie de troubles auto-immuns à l'aide d'anticorps ciblant les cellules B
AU2005220212B2 (en) * 1999-06-09 2008-12-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US7074403B1 (en) 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US8734792B2 (en) 2002-02-21 2014-05-27 Duke University Reagents and treatment methods for autoimmune diseases
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US10322176B2 (en) 2002-03-01 2019-06-18 Immunomedics, Inc. Subcutaneous administration of anti-CD74 antibody for systemic lupus erythematosus
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8137907B2 (en) 2005-01-03 2012-03-20 Cold Spring Harbor Laboratory Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
US9260530B2 (en) 2005-02-15 2016-02-16 Duke University Anti-CD19 antibodies and uses in B cell disorders
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
US11180559B2 (en) 2005-03-03 2021-11-23 Immunomedics, Inc. Subcutaneous anti-HLA-DR monoclonal antibody for treatment of hematologic malignancies
US10988539B2 (en) 2005-03-03 2021-04-27 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9359443B2 (en) 2005-04-06 2016-06-07 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseases
US8871216B2 (en) 2005-04-06 2014-10-28 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US9737617B2 (en) 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8906378B2 (en) 2005-04-06 2014-12-09 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases
US8426675B2 (en) 2005-05-31 2013-04-23 Cold Spring Harbor Laboratory Methods for producing microRNAs
US7993925B2 (en) 2005-05-31 2011-08-09 Cold Spring Harbor Laboratory Methods for producing microRNAs
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8664363B2 (en) 2006-03-06 2014-03-04 Medimmune, Llc Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2383297A1 (fr) 2006-08-14 2011-11-02 Xencor Inc. Anticorps optimisés ciblant le CD19
US8323653B2 (en) 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8883992B2 (en) 2006-09-08 2014-11-11 Medimmune, Llc Humanized anti-CD19 antibodies
US9896505B2 (en) 2006-09-08 2018-02-20 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2359139A2 (fr) * 2008-11-07 2011-08-24 National Jewish Health Diagnostic et traitement des maladies auto-immunes par ciblage des cellules b auto-immunes (« cbai »)
EP2359139A4 (fr) * 2008-11-07 2012-10-10 Nat Jewish Health Diagnostic et traitement des maladies auto-immunes par ciblage des cellules b auto-immunes (« cbai »)
CN105111312A (zh) * 2010-07-19 2015-12-02 国际药物发展生物技术公司 具有adcc和cdc功能及改善的糖基化特征的抗-cd19抗体
EP2409712A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté de fonctions ADCC et CDC et d'un profil de glycosylation amélioré
WO2012010561A1 (fr) 2010-07-19 2012-01-26 International - Drug - Development - Biotech Anticorps anti-cd19 à fonctionnalité adcc de profil de glycosylation amélioré
CN105111312B (zh) * 2010-07-19 2018-12-14 国际药物发展生物技术公司 具有adcc和cdc功能及改善的糖基化特征的抗-cd19抗体
WO2012010562A1 (fr) 2010-07-19 2012-01-26 International - Drug - Development - Biotech Anticorps anti-cd19 présentant des fonctions adcc et cdc, et un profil de glycosylation amélioré
US9663583B2 (en) 2010-07-19 2017-05-30 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
US9120856B2 (en) 2010-07-19 2015-09-01 International-Drug-Development Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
USRE49192E1 (en) 2010-07-19 2022-08-30 International—Drug—Development Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2409993A1 (fr) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anticorps Anti-CD19 doté d'une fonction ADCC et d'un profil de glycosylation amélioré
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9475883B2 (en) 2011-12-05 2016-10-25 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9963507B2 (en) 2011-12-05 2018-05-08 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9663576B2 (en) 2011-12-05 2017-05-30 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
US9493574B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10143756B2 (en) 2012-12-13 2018-12-04 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9522959B2 (en) 2012-12-13 2016-12-20 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11116846B2 (en) 2012-12-13 2021-09-14 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US11052156B2 (en) 2012-12-13 2021-07-06 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9499631B2 (en) 2012-12-13 2016-11-22 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9493573B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US11052081B2 (en) 2012-12-13 2021-07-06 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9855344B2 (en) 2012-12-13 2018-01-02 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9481732B2 (en) 2012-12-13 2016-11-01 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9629926B2 (en) 2012-12-13 2017-04-25 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9475884B2 (en) 2012-12-13 2016-10-25 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9458242B2 (en) 2012-12-13 2016-10-04 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10034950B2 (en) 2012-12-13 2018-07-31 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US9028833B2 (en) 2012-12-13 2015-05-12 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10130626B2 (en) 2012-12-13 2018-11-20 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10130718B2 (en) 2012-12-13 2018-11-20 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10849986B2 (en) 2012-12-13 2020-12-01 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US9375489B2 (en) 2012-12-13 2016-06-28 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10751420B2 (en) 2012-12-13 2020-08-25 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US11541047B2 (en) 2012-12-13 2023-01-03 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9226973B2 (en) 2012-12-13 2016-01-05 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10653793B2 (en) 2012-12-13 2020-05-19 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10682347B2 (en) 2012-12-13 2020-06-16 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US10709701B2 (en) 2012-12-13 2020-07-14 Immunomedics, Inc. Efficacy of anti-HLA-DR antibody drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9944703B2 (en) 2014-02-25 2018-04-17 Immunomedics, Inc. Humanized anti-CD22 antibody
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US9701748B2 (en) 2014-02-25 2017-07-11 Immunomedics, Inc. Humanized anti-CD22 antibody
US9518115B2 (en) 2014-02-25 2016-12-13 Immunomedics, Inc. Humanized anti-CD22 antibody
US10436788B2 (en) 2015-04-22 2019-10-08 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US11439620B2 (en) 2015-06-25 2022-09-13 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US10954305B2 (en) 2016-02-10 2021-03-23 Immunomedics, Inc. Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers
US11192955B2 (en) 2016-04-27 2021-12-07 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US10266605B2 (en) 2016-04-27 2019-04-23 Immunomedics, Inc. Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
US11634488B2 (en) 2017-07-10 2023-04-25 International—Drug—Development—Biotech Treatment of B cell malignancies using afucosylated pro-apoptotic anti-CD19 antibodies in combination with anti CD20 antibodies or chemotherapeutics

Also Published As

Publication number Publication date
AU7566991A (en) 1991-10-10

Similar Documents

Publication Publication Date Title
WO1991013974A1 (fr) Anticorps monoclonal et immunoconjugues de traitement et de detection de troubles des lymphocytes b
EP0479920B1 (fr) Nouveaux anticorps reagissant avec les carcinomes humains
EP0375562B1 (fr) Nouvel anticorps monoclonal pour les carcinomes humains
US7067128B2 (en) Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5489516A (en) Hybridoma and monoclonal antibody specific for human stem cell factor receptor and methods of use of the monoclonal antibody for detection of stem cell factor receptors
AU619232B2 (en) Novel antibodies
US5443953A (en) Preparation and use of immunoconjugates
AU639458B2 (en) Novel monoclonal antibody to novel antigen associated with human tumors
EP0856054B1 (fr) Anticorps monoclonal br110 et ses utilisations
CA2199740A1 (fr) Anticorps monoclonaux diriges contre des antigenes associes au carcinome du colon humain et utilisation desdits anticorps
WO1995026364A1 (fr) Anticorps monoclonaux reconnaissant le recepteur 'tie', et leurs applications
JP2001521520A (ja) 抗α▲下v▼β▲下3▼インテグリン抗体アンタゴニスト
Sharifi et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
US5407805A (en) Monoclonal antibody reactive to various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
US5411884A (en) Monoclonal antibody L53 which recognizes a human tumor-associated antigen
US5053491A (en) Monoclonal antibodies and cell lines for parathyroid tissue-specific antigen
EP0227391A2 (fr) Techniques de radiovisualisation spécifique de la parathyroide
PL168700B1 (pl) Sposób wytwarzania nowego ludzko-mysiego chimerycznego przeciwcialamonoklonalnego PL
JPH07181186A (ja) プレターゲッティング用キット及び方法
WO1990006772A1 (fr) Nouveaux anticorps monoclonaux de carcinomes humains
WO1994006016A1 (fr) Nouveau marqueur de cellules tumorales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

NENP Non-entry into the national phase

Ref country code: CA